Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T22:51:20.490Z.
Calculation as of: 2026-10-06T22:51:20.490Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8e2f3ec51e074b036058196f7f903a3cac1545bb57f25a27b7ce4fd0c255fbf9
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$247.27M
EBITDA Yield
N/A
TTM Avg
1.55%
3Y Avg
0.84%
5Y Avg
1.10%
Market Cap
$248.50M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$241.94M
EBITDA Yield
N/A
TTM Avg
3.52%
3Y Avg
3.58%
5Y Avg
4.02%
Market Cap
$255.88M
EBITDA Yield
0.21%
TTM Avg
12.97%
3Y Avg
7.82%
5Y Avg
5.93%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Galectin Therapeutics Inc. (GALT) | $247.62M | N/A | N/A | N/A | N/A |
| Sol-Gel Technologies Ltd. (SLGL)vs › | $247.27M | N/A | 1.55% | 0.84% | 1.10% |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $248.50M | N/A | N/A | N/A | N/A |
| Upstream Bio, Inc. (UPB)vs › | $249.79M | N/A | N/A | N/A | N/A |
| Lifecore Biomedical, Inc. (LFCR)vs › | $241.94M | N/A | 3.52% | 3.58% | 4.02% |
| Q32 Bio Inc. (QTTB)vs › | $241.39M | 15.60% | 32.49% | 32.49% | 32.49% |
| Quantum-Si incorporated (QSI)vs › | $241.34M | N/A | N/A | N/A | N/A |
| Anika Therapeutics, Inc. (ANIK)vs › | $255.88M | 0.21% | 12.97% | 7.82% | 5.93% |
| Century Therapeutics, Inc. (IPSC)vs › | $239.02M | N/A | N/A | N/A | N/A |
| High Tide Inc. (HITI)vs › | $239.01M | 7.76% | 5.41% | 5.10% | 3.84% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
